$1.07
13.09% today
Nasdaq, Feb 28, 05:07 pm CET
ISIN
US79400X1072
Symbol
SLRX
Sector
Industry

Salarius Pharmaceuticals Inc Stock price

$1.23
-1.23 50.00% 1M
-0.48 28.07% 6M
-0.61 33.15% YTD
-3.73 75.19% 1Y
-78.79 98.46% 3Y
-172.69 99.29% 5Y
-86,923.77 100.00% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.22 15.17%
ISIN
US79400X1072
Symbol
SLRX
Sector
Industry

Key metrics

Market capitalization $1.95m
Enterprise Value $-1.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.19
P/B ratio (TTM) P/B ratio 0.61
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-5.22m
Free Cash Flow (TTM) Free Cash Flow $-5.29m
Cash position $3.28m
EPS (TTM) EPS $-8.19
P/E forward negative
Short interest 0.66%
Show more

Is Salarius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Financial data from Salarius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.55 4.55
31% 31%
-
- Research and Development Expense 0.65 0.65
94% 94%
-
-5.21 -5.21
72% 72%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.22 -5.22
72% 72%
-
Net Profit -4.99 -4.99
72% 72%
-

In millions USD.

Don't miss a Thing! We will send you all news about Salarius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Salarius Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
25 days ago
HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas...
Neutral
Business Wire
about 2 months ago
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse mer...

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Head office United States
CEO David Arthur
Employees 2
Founded 2014
Website salariuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today